The Microsidd HCV Rapid Test Kit – 50 Tests is a professional-use in-vitro diagnostic rapid test intended for the qualitative detection of antibodies to Hepatitis C Virus (anti-HCV) in compatible human specimens.
The test uses rapid immunochromatographic lateral-flow technology to support initial hepatitis C antibody screening in diagnostic laboratories, hospitals, clinics, blood-bank environments where applicable, antenatal screening programmes, public-health programmes and other professional healthcare settings.
This institutional 50-test pack is intended for trained healthcare and laboratory personnel.
Important: A reactive anti-HCV screening result does not by itself confirm current hepatitis C infection. Appropriate follow-up testing, generally including an HCV RNA test, is required to determine whether active HCV infection is present.
Brand: Microsidd
Product: HCV Rapid Test Kit
Product Type: Hepatitis C Antibody Rapid Test
Category: Rapid Diagnostic Tests / Infectious Disease Testing
Target Marker: Anti-HCV Antibodies
Disease Area: Hepatitis C
Technology: Immunochromatographic Lateral Flow
Result Type: Qualitative Screening
Format: Single-Use Rapid Test Device
Pack Size: 50 Tests
Intended Use: Professional In-Vitro Diagnostic Use Only
Seller / Brand Owner: Microsidd India
Location: RT Nagar, Bengaluru, Karnataka, India
Specimen type, specimen volume, buffer quantity, reading time, sensitivity/specificity and storage temperature should be taken only from the package insert supplied with the exact current Microsidd HCV 50T batch.
The Microsidd HCV Rapid Test is an antibody-screening test designed to detect anti-HCV antibodies associated with exposure to Hepatitis C Virus.
It is used as an initial screening test.
A reactive antibody result means that antibodies associated with HCV have been detected, but it does not determine whether the person:
Determining current infection requires appropriate follow-up testing.
This distinction is essential.
| Test | What It Detects | Main Meaning |
|---|---|---|
| Anti-HCV Rapid Test | Antibodies to HCV | Evidence of previous or current exposure |
| HCV RNA Test | Viral RNA | Evidence of current viraemic infection |
| HCV Core Antigen | HCV core antigen | May support detection of current infection in appropriate algorithms |
A reactive anti-HCV rapid test is therefore a screening result, not a complete diagnosis of active hepatitis C.
The Microsidd HCV Rapid Test is designed for qualitative detection of:
Antibodies to Hepatitis C Virus
Each institutional sales pack contains:
50 tests
making it appropriate for laboratories, hospitals, clinics and screening programmes with higher testing requirements.
The immunochromatographic format supports rapid visual screening without requiring an ELISA reader.
Each test device is intended for one specimen and one test only.
This 50-test listing is intended for trained healthcare and laboratory personnel rather than unsupervised home self-testing.
| Specification | Details |
|---|---|
| Brand | Microsidd |
| Product | HCV Rapid Test Kit |
| Pack Size | 50 Tests |
| Target Marker | Anti-HCV Antibodies |
| Disease Area | Hepatitis C |
| Test Type | Qualitative Rapid Screening |
| Technology | Lateral Flow Immunochromatography |
| Format | Rapid Test Device / Cassette, as supplied |
| Result Classification | Reactive / Non-Reactive / Invalid according to IFU |
| Single Use | Yes |
| Intended Users | Trained Healthcare & Laboratory Personnel |
| Intended Use | Professional IVD |
| Specimen | Verify exact current IFU |
| Reading Time | Verify exact current IFU |
| Storage | Verify carton label / current IFU |
The test uses a membrane-based immunochromatographic principle.
During testing:
The exact procedure and line interpretation must follow the current package insert supplied with the test.
A typical professional testing sequence is:
Do not copy sample volume, number of buffer drops or reading time from another HCV test simply because the cassettes look similar.
A valid non-reactive result generally means that the required control indicator appears and the test does not detect anti-HCV antibodies under the assay conditions.
A non-reactive result does not exclude infection in every circumstance, particularly after recent exposure before antibodies have become detectable.
A reactive result means that anti-HCV antibodies have been detected.
This can occur in someone with:
A reactive antibody result should therefore proceed to appropriate follow-up testing.
If the required control indicator does not appear, the test is invalid.
The specimen should be retested using a new device according to the IFU.
A reactive anti-HCV result should generally be followed by testing that determines whether current HCV infection is present.
This commonly involves:
HCV RNA / NAT testing
The follow-up pathway should be determined by qualified healthcare professionals and the applicable clinical/testing protocol.
| Stage | Test | Purpose |
|---|---|---|
| Initial Screening | Anti-HCV Antibody Test | Detects antibodies indicating exposure |
| Current Infection Assessment | HCV RNA / NAT | Detects active viraemia |
| Clinical Evaluation | Additional Laboratory / Medical Assessment | Evaluates liver health and treatment needs |
The Microsidd HCV Rapid Test performs the initial antibody-screening step.
The Microsidd HCV 50 Test Pack is intended for appropriately trained personnel working in settings such as:
This product is for professional IVD use only.
The test may support appropriate workflows for:
Hepatitis C screening can be relevant during antenatal care.
Antenatal care provides an opportunity to identify maternal HCV exposure and, where the antibody screen is reactive, arrange appropriate follow-up testing to determine whether current infection is present.
A reactive anti-HCV antibody result during pregnancy does not by itself establish active HCV infection.
Follow-up testing and maternal care should be coordinated by qualified healthcare professionals.
The Microsidd HCV Rapid Test Kit – 50 Tests forms part of the broader Microsidd Maternal & Infectious Disease Rapid Testing Hub, which connects professional infectious-disease screening with the antenatal-care pathway.
https://microsidd.com/blogs/knowledge-hub/antenatal-infection-screening-hiv-syphilis-hepatitis-b-hcv
The Microsidd professional maternal-testing architecture is:
Pregnancy Confirmed
↓
First Antenatal Visit
↓
Maternal & Infectious Disease Screening
↓
HIV • Syphilis • HBsAg • HCV
↓
Individual Professional Screening Guides
↓
Professional Rapid-Test Products
↓
Confirmatory / Laboratory Testing Where Required
HCV rapid tests commonly screen for anti-HCV antibodies.
A reactive anti-HCV result requires appropriate follow-up, generally including HCV RNA testing, to determine whether current infection is present.
Professional HIV rapid tests may screen for HIV-1/HIV-2 antibodies or other HIV-related markers depending on the assay.
A reactive screening result must follow the applicable HIV testing algorithm.
HBsAg testing detects hepatitis B surface antigen and is different from hepatitis B antibody testing.
Syphilis rapid tests commonly detect antibodies associated with Treponema pallidum.
Interpretation and follow-up depend on the exact test and the applicable clinical algorithm.
HIV, syphilis, hepatitis B and hepatitis C are four separate infections.
They may be considered together within antenatal infection-screening pathways, but:
one test cannot be used to infer the result of another infection.
HCV should also not be described as part of WHO’s HIV–syphilis–hepatitis B Triple Elimination framework; it is an additional important infectious-disease screening consideration according to applicable guidance.
https://microsidd.com/blogs/knowledge-hub/antenatal-infection-screening-hiv-syphilis-hepatitis-b-hcv
https://microsidd.com/collections/rapid-test
https://microsidd.com/collections/blood-bank-range
https://microsidd.com/products/hcv-rapid-test-kit
Once the new HIV and HBsAg 50T URLs are live, also interlink:
Microsidd HIV 1 & 2 Rapid Test 50T
↕
Microsidd HBsAg Rapid Test 50T
↕
Microsidd HCV Rapid Test 50T
↕
Microsidd Syphilis Rapid Test 50T
This creates the professional infection-screening cluster.
Follow the exact conditions printed on the product carton and current package insert.
General good practice includes:
The supplied IFU overrides general website guidance.
During transportation:
Professional testing programmes should follow appropriate quality-assurance procedures including:
Do not report an invalid test.
Microsidd India supplies professional rapid diagnostic tests, blood-bank products and laboratory diagnostics to healthcare professionals and institutions.
Benefits include:
✓ Microsidd professional infectious-disease range
✓ 50-test institutional pack
✓ Integration with Microsidd maternal and infectious-disease content
✓ Related HIV, HBsAg and syphilis screening products
✓ Bengaluru-based customer support
✓ GST invoice where applicable
✓ Institutional supply support subject to availability
✓ Online ordering across serviceable locations in India
✓ Clear screening-versus-confirmation guidance
Microsidd India supplies professional HCV rapid test kits in Bengaluru and serves laboratories, hospitals, clinics and institutional healthcare customers across serviceable locations in India.
Relevant search phrases include:
HCV rapid test Bangalore
Hepatitis C test kit Bengaluru
HCV rapid test 50 tests India
anti-HCV rapid test Bangalore
professional HCV test kit Bengaluru
Hepatitis C antibody test near me
Business Name: Microsidd India
Address: #09, Green Chambers, 14th Cross, RT Nagar, Bengaluru – 560032, Karnataka, India
Phone / WhatsApp: +91 63667 72288
Email: support@microsidd.com
Website: https://microsidd.com
Working Hours: Monday to Saturday, 10:00 AM – 6:00 PM IST
https://www.youtube.com/channel/UCun9gCID17Z5kK65W6JtIdg?sub_confirmation=1
https://whatsapp.com/channel/0029Va5lCoi1nozBZBL1gx3P
It is designed for qualitative screening for antibodies to Hepatitis C Virus – anti-HCV.
50 tests.
This product should be described as an anti-HCV antibody screening test, not as a direct HCV RNA test.
No.
A reactive antibody result indicates previous exposure to HCV but does not by itself establish whether current viraemic infection is present.
Appropriate nucleic-acid testing for:
HCV RNA
is commonly used to establish current infection.
Yes.
HCV antibodies may remain detectable even when the person no longer has active infection.
No.
HCV viral-load assessment requires molecular testing.
No.
Genotype assessment requires separate laboratory testing where clinically required.
HCV screening can form part of antenatal infection-screening pathways according to applicable guidance and clinical protocols.
No.
A maternal reactive antibody screen does not determine infant infection status.
Further maternal testing and appropriate infant follow-up are required.
The WHO Triple Elimination framework focuses on:
HIV, syphilis and hepatitis B.
HCV is a separate infection that may also be considered in antenatal screening according to applicable guidelines.
No.
This listing is for professional IVD use only.
Use only the specimen types specified in the exact package insert supplied with the current 50-test batch.
Follow the current Microsidd HCV IFU.
Use only the buffer quantity specified in the package insert.
Follow the exact manufacturer-defined reading window printed in the current IFU.
If the required control indicator does not appear, the test cannot be interpreted and should be repeated with a new device.
No.
No.
Each device is single use.
This product is non-returnable and non-exchangeable.
Please verify the product name, test marker, pack size, specimen requirements, intended use and product specifications before placing your order.
Professional customers should verify that the test configuration is suitable for their laboratory, hospital or institutional testing protocol.
Genuine cases involving an incorrect product received will be handled separately according to Microsidd.com's applicable policies and applicable law.
An original, continuous, unedited and uncut unboxing video is compulsory for making any claim regarding an incorrect product received.
The Microsidd HCV Rapid Test Kit – 50 Tests is intended for professional in-vitro diagnostic screening use only.
A reactive anti-HCV result is not sufficient by itself to establish current hepatitis C infection.
Reactive results should undergo appropriate follow-up testing, generally including HCV RNA testing, according to the applicable clinical and laboratory pathway.
A non-reactive result does not exclude every possible recent exposure.
Pregnancy-related testing and management should be supervised by qualified healthcare professionals.
All patient specimens and used test materials should be considered potentially infectious and handled according to appropriate biosafety procedures.
